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OBJECTIVES : Bone marrow adipose tissue has been associated with low bone mineral density. However, no data
exist regarding marrow adipose tissue in primary hyperparathyroidism, a disorder associated with bone loss in
conditions of high bone turnover. The objective of the present study was to investigate the relationship
between marrow adipose tissue, bone mass and parathyroid hormone. The influence of osteocalcin on the
homeostasis model assessment of insulin resistance was also evaluated.
METHODS: This was a cross-sectional study conducted at a university hospital, involving 18 patients with
primary hyperparathyroidism (PHPT) and 21 controls (CG). Bone mass was assessed by dual-energy x-ray
absorptiometry and marrow adipose tissue was assessed by 1H magnetic resonance spectroscopy. The
biochemical evaluation included the determination of parathyroid hormone, osteocalcin, glucose and insulin
levels.
RESULTS: A negative association was found between the bone mass at the 1/3 radius and parathyroid hormone
levels (r = -0.69; po0.01). Marrow adipose tissue was not significantly increased in patients (CG = 32.8±11.2% vs
PHPT = 38.6±12%). The serum levels of osteocalcin were higher in patients (CG = 8.6±3.6 ng/mL vs PHPT =
36.5±38.4 ng/mL; po0.005), but no associations were observed between osteocalcin and insulin or between
insulin and both marrow adipose tissue and bone mass.
CONCLUSION: These results suggest that the increment of adipogenesis in the bone marrow microenvironment
under conditions of high bone turnover due to primary hyperparathyroidism is limited. Despite the increased
serum levels of osteocalcin due to primary hyperparathyroidism, these patients tend to have impaired insulin
sensitivity.
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’ INTRODUCTION
Parathyroid hormone (PTH) is a crucial element in the
complex process of bone development and maintenance.
Constantly high (1) or low (2) serum levels of PTH have
detrimental effects on bone. Conversely, intermittent expo-
sure of bone cells to high circulating levels of PTH causes
bone remodeling to become an anabolic response (3).
While improvements in imaging technology allow visua-
lization of even mild states of primary hyperparathyroidism
(PHPT) that systemically affect the skeleton, a gap exists in
the knowledge of the mechanism of bone loss in PHPT.
Recently, concomitant increases in bone marrow adiposity in
several conditions have been shown to be associated with a
negative bone balance (4), such as secondary osteoporosis
due to anorexia nervosa (5). These disorders are associated
with low bone turnover and decreased osteoblast activity,
whereas in PHPT, bone loss typically occurs within a
microenvironment of unrestrained osteoblast function (6).
Because osteoblasts and adipocytes originate from the same
mesenchymal stem cells, knowledge of marrow composition
in states of high bone turnover is crucial for understanding,
at least in part, the mechanism of bone loss in PHPT.
Osteocalcin (OC) produced by osteoblasts is suggested to
be the bone link in a new axis involving bone and b-cellDOI: 10.6061/clinics/2016(08)09
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secretion of insulin, as well as insulin sensitivity (7, 8). While
insulin directly stimulates osteoblast activity, OC regulates
insulin secretion and action. Evidence of insulin resistance (9)
and an increased incidence of diabetes mellitus have been
found in PHTP patients (10). Impaired insulin action has
been attributed to high calcium levels and hypophosphatemia
in previous studies (11). However, serum levels of OC are
elevated in PHPT patients and decrease after successful
parathyroidectomy (12).
Therefore, the primary objective of the present study was
to measure bone marrow adipose tissue (BMAT) in patients
with PHPT. Because the association of serum OC levels with
insulin resistance has been scarcely evaluated in PHPT
patients, the second objective of the present study was to
investigate the relationship between serum levels of OC and
both insulin and the homeostasis model assessment of
insulin resistance (HOMA-IR).
’ MATERIALS AND METHODS
Subjects
The study was conducted on two groups, including
control (CG, n = 21) and PHPT patients (PHPTG, n = 18),
who were matched for gender, age, weight, height and body
mass index. All patients were followed-up at the outpatient
clinic of Osteometabolic Disorders of the University Hospi-
tal, Ribeirão Preto Medical School, Universidade de São
Paulo. The exclusion criteria for both groups were as follows:
alcohol abuse, smoking, hepatic or renal disease, or using
medications known to interfere with mineral metabolism
(e.g., anabolic steroids, glucocorticoids, anticonvulsants,
diuretics or medications for the treatment of osteoporosis).
The Research Ethics Committee of the University Hospital
approved the study (protocol #13898/2010) and all partici-
pants gave written informed consent.
Methods
A blood sample was obtained under standard conditions
between 8 and 9 am after an overnight fast. Serum aliquots
were used for the determination of biochemical, hormonal
and bone-related parameters. The biochemical parameters
[albumin, alkaline phosphatase (ALP), calcium, creatinine,
ionized calcium, glucose and phosphorus levels] were
immediately measured with an autoanalyzer (CT 600i,
Wiener Lab, Buenos Aires, Argentina). Individual aliquots
for the determination of insulin, iPTH, 25-hidroxy vitamin D
(25-OHD) and OC were frozen at -70o C until measurements
were obtained.
Insulin was measured by an immunoradiometric assay
(Insulin IRMA – Beckman Coulter, Immunotech, Prague,
Czech Republic). The Immulite I system (Siemens, Los
Angeles, CA, USA) was used to determine iPTH levels,
while bone-specific alkaline phosphatase (BAP) and 25-OHD
levels were determined by chemiluminescence (Liaison,
Diasorin, Saluggia, VC, Italy). OC levels were determined
by an immunoenzymometric assay (hOst ELISA – Diasource,
Louvain la Neuve, Belgium).
Dual energy X-ray absorptiometry (DXA) and 1H magnetic
resonance spectroscopy (MRS)
The bone mineral density (BMD) of the lumbar spine (L1-L4),
femoral neck, total hip and 1/3 radius were determined by
DXA (Discovery, Hologic Inc., Bedford, MA, USA). The
precision errors were 1.2% for L1-L4, 2.3% for the femoral
neck, 2.7% for the total hip and 1.7% for the 1/3 radius.
The fat fraction (FF) was estimated by proton magnetic
resonance spectroscopy (1H-MRS) using a 1.5 Tesla scanner,
as previously described (13). In brief, a sagittal spin echo
sequence (TR/TE = 3900/120 ms) was acquired to localize
the L3 vertebral body and to identify pre-existing abnorm-
alities of the lumbar vertebrae. A voxel measuring
20 20 20 mm3 was placed within the L3 vertebral body.
Single-voxel 1H-MRS data were acquired using a PRESS
sequence without water suppression with the following
parameters: TR of 1600 ms, 16 averages, 2048 data points,
and a spectral bandwidth of 1500 Hz. The spectra were
acquired with several echo times, i.e., TE = 25, 35, 50, 60 and
80 ms, to consider the relaxation effect on the water and lipid
content estimation. The spectra were processed with the LC-
model software (http://s-provencher.com/pages/lcmodel.
shtml). A mean lipid peak of 1.3 ppm was used for fat
quantification. The FF was estimated as the lipid-lipid plus
water ratio without the relaxation effect.
Table 1 - Clinical characteristics and biochemical evaluation of control subjects (CG) and patients with primary hyperparathyroidism
(PHPTG).
CG (n = 21) PHPTG (n = 18) Estimated difference [C.I. (95%)] p-value
Age (years) 50.1±9.4 51.1±11.3 -0.96 (-7.66;5.74) 0.77
Weight (kg) 73.3±13.6 76.5±21.6 -3.2 (-14.81;8.29) 0.57
Height (m) 1.65±0.1 1.61±0.1 0.04 (-0.01;0.10) 0.14
BMI (kg/m2) 26.8±4.1 29.8±6.8 -2.9 (-6.52;0.64) 0.10
Total calcium (mg/dL) 9.6±0.7* 11.9±1.1 -2.3 (-2.88;-1.66) o0.01
Albumin (g/dL) 4.4±0.3 4.2±0.3 0.1 (-0.36;0.04) 0.11
Albumin corrected calcium (mg/dL) 9.31±0.76* 11.6±1.3 -2.41 (1.76;3.06) o0.01
Phosphorus (mg/dL) 3.4±0.4* 2.6±0.6 0.8 (0.48;1.15) o0.01
Alkaline phosphatase (U/L) 174.2±49.4* 364.4±252.0 -190.2 (-303.9;-76.42) o0.005
Creatinine (mg/dL) 0.8±0.2* 1.1±0.4 -0.3 (-0.06;0.46) o0.05
iPTH (pg/mL) 44.5±16.7 459.8±462.2 -413.3 (-641.8;-184.9;) o0.005
Log10 iPTH (pg/mL) 1.62±0.17* 2.46±0.42 -0.85 (-1.049; -0.66) o0.01
25-hydroxyvitamin D (ng/mL) 24.7±3.9* 18.3±4.8 6.4 (3.6;9.2) o0.01
Osteocalcin (ng/mL) 8.65±3.6* 36.5±38.4 -27.03 (-45.66;-8.39) o0.05
Log10 Osteocalcin (ng/mL) 0.89±0.22* 1.3±0.52 -0.34 (-0.59;-0.1) o0.05
Glucose (mg/dL) 90.6±7.3 95.1±11.0 -4.5 (-10.51;1.43) 0.13
Insulin (mIU/mL) 8.5±3.4 15.5±15.6 -7.0 (-14.21; 0.29) 0.059
HOMA-IR 1.9±0.8 3.7±4.1 -1.8 (-3.72; 0.09) 0.06
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Statistical analysis
Student’s t-test was used to compare the results obtained
for the two groups. The Pearson correlation test was used to
evaluate the relationship between two parameters. Given the
skewed distribution of iPTH and OC levels, a base-10
logarithm transformation was used for the analysis. The
analysis was performed using R software version 2.15.3
(http://www.R-project.org). The results are reported as the
means ± standard deviations, with the level of significance
set at p o 0.05.
’ RESULTS
Table 1 shows the clinical characteristics and results of the
laboratory tests for both groups. Serum calcium, total
alkaline phosphatase and iPTH levels were significantly
increased in the PHPTG, while the circulating levels of
inorganic phosphorus and 25-OHD were higher in the CG.
Sixteen PHPTG subjects (88.9%) had osteoporosis as deter-
mined by the BMD T-Score. Table 1 shows that the serum
levels of OC were approximately 4 times higher in the
PHPTG than in the CG (p o 0.005).
The CG showed a negative correlation between serum
calcium and iPTH levels (p o 0.005, r = -0.59; CI = -0.81 to
-0.20) (Figure 1a). Conversely, PHPTG subjects exhibited a
positive association of iPTH with calcium levels (p o 0.01,
r = 0.61; CI = 0.36 0.88) (Figure 1b) and OC (p o 0.0001;
r = 0.82; CI = 0.59 to 0.93) (Figure 1d). No relationship was
observed between the serum levels of iPTH and 25-OHD.
PHPT patients exhibited lower a BMD of the 1/3 radius than
CG subjects (CG = 0.676 ± 0.074 vs PHTPG = 0.578 ± 0.132
g/cm2, p o 0.01; CI = -0.17 to -0.03). No significant difference
was found in bone mass between the two groups in the lumbar
spine (CG = 0.958 ± 0.106 vs PHPTG = 0.879 ± 0.194 g/cm2),
femoral neck (CG = 0.775 ± 0.125 vs PHPTG = 0.752 ± 0.190
g/cm2) or total hip (CG = 0.917 ± 0.090 vs PHPTG = 0.862 ±
0.180 g/cm2). Negative correlations of iPTH levels with the BMD
of the 1/3 radius (r = -0.69; p o 0.005; CI = -0.87 to -0.3348),
lumbar spine (r = -0.483; p o 0.05, CI = -0.77 to -0.02), femoral
neck (r = -0.537; po 0.05; CI = -0.80 to -0.09) and total hip (po
0.05; r = -0.57; CI = -0.82 to -0.14) were observed only in the
PHPTG. The BMD was not associated with serum levels of
25-OHD in either group.
The BMAT did not differ significantly between groups
(CG = 32.8 ± 11.2% vs PHPTG = 38.6 ± 12.4%) (Figure 2a).
Figure 1 - Correlation between the iPTH serum levels (log iPTH) and the calcium serum levels in the control group (a) and in patients
with primary hyperparathyroidism (b). Correlation between the iPTH (log iPTH) serum levels and the osteocalcin (log osteocalcin)
serum levels in the control group (c) and in patients with primary hyperparathyroidism (d).
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A negative correlation was observed between lumbar spine
BMD and BMAT only in the PHPTG (p o 0.05; r = -0.59;
CI = -0.75 to 0.02) (Figure 2b and 2c). While a negative
correlation was observed between BMAT values and serum
levels of PTH in the CG, no relationship between these
parameters was observed in the PHPTG. The BMATwas not
associated with serum levels of 25-OHD or insulin or
HOMA-IR values in the two groups.
Serum glucose levels were similar in the two groups.
However, the PHPTG tended to have higher serum insulin
levels (p = 0.059) and HOMA-IR values (p = 0.06) than the
control group. No correlations were observed for serum
levels of insulin, glucose and HOMA-IR values with serum
levels of OC.
’ DISCUSSION
Recently, new findings in animal models have shown that
bone and mineral metabolism are intimately linked to energy
metabolism. For instance, the total or partial deletion of
vitamin D receptors in mice leads to bone loss but also
produces a lean phenotype and metabolic advantages (14, 15).
Undercarboxylated OC (unOC) has been shown to improve
glucose tolerance and insulin resistance in mice with insulin
receptor deletion specifically in osteoblasts (7). Finally, bone
marrow contains a unique type of adipose tissue with an
unknown function. It has been hypothesized that BMAT may
provide energy support for bone cells during bone develop-
ment, but it can also have detrimental effects in several
conditions, such as aging, hypercortisolism and food depriva-
tion (4). The present study demonstrated that PHPT patients
do not show significantly increased BMAT but exhibit a
negative relationship between BMAT and BMD in the lumbar
spine. In addition, despite their increased serum OC levels,
PHPT patients show a concomitant tendency toward high
serum insulin levels and HOMA-IR values. In other words,
high serum OC levels are not associated with improved
insulin sensitivity in PHPT.
Consistent with previous studies, an evaluation based on
DXA showed that PHPT has a greater effect on cortical bone
than trabecular bone (16, 17). Bone mass was significantly lower
in PHPT patients than in controls only at the 1/3 radius, while a
non-significant difference was observed at the other sites. It
should be emphasized that this point has been recently
considered important because improvements in imaging tech-
nology have shown that trabecular bone is not spared in PHPT
Figure 2 - Bone marrow adipose tissue in the control group and in patients with primary hyperparathyroidism (a). Correlation between
bone marrow adipose tissue (BMAT) and the bone mineral density of the lumbar spine in the control group (b) and in patients with
primary hyperparathyroidism (c).
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(18). In support of this new evidence, the present study showed
a negative relationship of serum PTH levels not only with the
BMD of the 1/3 radius but also with the lumbar spine BMD, a
bone site predominantly composed of trabecular bone.
BMATwas not significantly increased in PHPT patients, but a
negative correlation was found between BMAT and BMD at the
lumbar spine. Previous studies investigating the content of
BMAT in two conditions causing secondary osteoporosis (i.e.,
anorexia nervosa and hypercortisolism) reported a significantly
increased amount of BMAT. In contrast to PHPT, anorexia
nervosa and glucocorticoid-induced osteoporosis result in low
osteoblastic activity. Most likely, these different results reflect the
diverse mechanisms of bone loss that depend on the circum-
stances. In vitro studies that have investigated the catabolic effect
of PTH have suggested that PTH-induced osteoclast activity
requires the presence of osteoblastic cells (19). Moreover,
previous studies have also shown that PTH enhances the
commitment of progenitor cells to differentiate into osteoblasts
(20). Therefore, it can be hypothesized that the imbalance of
osteogenesis and adipogenesis is less accentuated in PHPT than
in anorexia nervosa and hypercortisolism.
Recently, two independent groups have used animal models
to show that OC, particularly its unOC form, is a potential
systemic modulator of glucose metabolism (7, 8). However,
contradictory results have been observed in clinical investiga-
tions regarding the role of total OC and unOC in glucose
metabolism. Pittas et al. observed that OC is negatively
associated with fasting circulatory levels of insulin and glucose
in individuals older than 65 years (21). Conversely, antiresorptive
drugs, such as alendronate (22), which indirectly reduce OC
levels, do not impair glucose tolerance. Consistent with the latter
study, our data did not show an association between the
HOMA-IR index and the total OC level or a relationship
between OC and glucose or insulin. Moreover, previous studies
have indicated that hypercalcemia (23) and hypophosphatemia
(11) could be directly involved with the emergence of
hyperinsulinemia in PHPT patients. Therefore, the role of OC
in the circulatory levels of insulin as a causative or concomitant
factor in primary hyperparathyroidism still needs to be
determined. Taken together, our results show that despite their
high serum levels of OC, PHPT patients have no improvement
in insulin sensitivity. In addition, the present study reinforces
recent data showing no relationship between BMAT and both
serum insulin levels and HOMA-IR values (13).
The present study shows that bone marrow adipose tissue is
not significantly increased in patients with PHPT. These results
suggest that bone loss in PHPT occurs at a lower imbalance
between osteoblastogenesis and adipogenesis in the bone
marrow microenvironment than in anorexia nervosa. Although
iPTH is strongly correlated with serum OC levels, no relation-
ship exists between serum OC levels and both serum glucose
levels and HOMA-IR values. In addition, no correlation exists
between BMAT and insulin resistance.
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